Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qin Lin

Showing results (631-640 of 641) with videos related to

Pageof 65
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 7, 2021
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 TrialHongcheng Zhu, Eleonor Rivin Del Campo, Jinjun Ye, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Frontiers in Oncology|June 27, 2022
18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment IndividualizationSebastian Zschaeck, Julian Weingärtner, Elia Lombardo, et al.
Cancer Letters|August 22, 2025
A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinomaMan Hu, Xia Li, Hong Feng, et al.
Signal Transduction and Targeted Therapy|April 16, 2021
Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndromeHao Li, Xia-Ming Jiang, Ning Cui, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 65

Showing results (631-640 of 641) with videos related to

Sort By:
Pageof 65
International Journal of Radiation Oncology, Biology, Physics|March 7, 2021
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 TrialHongcheng Zhu, Eleonor Rivin Del Campo, Jinjun Ye, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Frontiers in Oncology|June 27, 2022
18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment IndividualizationSebastian Zschaeck, Julian Weingärtner, Elia Lombardo, et al.
Cancer Letters|August 22, 2025
A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinomaMan Hu, Xia Li, Hong Feng, et al.
Signal Transduction and Targeted Therapy|April 16, 2021
Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndromeHao Li, Xia-Ming Jiang, Ning Cui, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 65